Grifols SA ADR (GRFS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Grifols SA ADR stock (GRFS) is currently trading at $7.60. Grifols SA ADR PE ratio is 13.81. Grifols SA ADR PS ratio (Price-to-Sales) is 0.83. Analyst consensus price target for GRFS is $12.53. WallStSmart rates GRFS as Moderate Buy.
- GRFS PE ratio analysis and historical PE chart
- GRFS PS ratio (Price-to-Sales) history and trend
- GRFS intrinsic value — DCF, Graham Number, EPV models
- GRFS stock price prediction 2025 2026 2027 2028 2029 2030
- GRFS fair value vs current price
- GRFS insider transactions and insider buying
- Is GRFS undervalued or overvalued?
- Grifols SA ADR financial analysis — revenue, earnings, cash flow
- GRFS Piotroski F-Score and Altman Z-Score
- GRFS analyst price target and Smart Rating
Grifols SA ADR
📊 No data available
Try selecting a different time range
GRFS Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Grifols SA ADR (GRFS)
GRFS trades at a significant discount to its Graham intrinsic value of $29.48, offering a 69% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Grifols SA ADR (GRFS) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, operating margin, price/sales. Concerns around return on equity and revenue growth. Overall metrics suggest strong investment potential with favorable risk/reward.
Grifols SA ADR (GRFS) Key Strengths (7)
Growing significantly faster than its price suggests
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Earnings per share surging 750.00% year-over-year
Strong operational efficiency: $20 kept per $100 revenue
58.09% held by institutions, strong professional interest
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Grifols SA ADR (GRFS) Areas to Watch (3)
Revenue growing slowly at 4.00% annually
Very thin margins, barely profitable
Low profitability relative to shareholder equity
Grifols SA ADR (GRFS) Detailed Analysis Report
Overall Assessment
This company scores 71/100 in our Smart Analysis, earning a B grade. Out of 10 metrics analyzed, 7 register as strengths (avg 9.0/10) while 3 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Price/Sales, Price/Book. Valuation metrics including PEG Ratio (0.23), Price/Sales (0.83), Price/Book (0.87) suggest the stock is attractively priced. Profitability is solid with Operating Margin at 20.40%. Growth metrics are encouraging with EPS Growth at 750.00%.
The Bear Case
The primary concerns are Revenue Growth, Profit Margin, Return on Equity. Growth concerns include Revenue Growth at 4.00%, which may limit upside. Profitability pressure is visible in Return on Equity at 5.89%, Profit Margin at 4.96%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 5.89% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 4.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of PEG Ratio and Price/Sales makes a compelling case at current levels. The key risk is Revenue Growth, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GRFS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
GRFS's Price-to-Sales ratio of 0.83x trades 39% below its historical average of 1.37x (32th percentile). The current valuation is 80% below its historical high of 4.14x set in Jun 2014, and 232% above its historical low of 0.25x in Jan 2025. Over the past 12 months, the PS ratio has expanded from ~0.3x, reflecting growing market expectations outpacing revenue growth.
Compare GRFS with Competitors
Top DRUG MANUFACTURERS - GENERAL stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Grifols SA ADR (GRFS) · HEALTHCARE › DRUG MANUFACTURERS - GENERAL
The Big Picture
Grifols SA ADR is a strong growth company balancing expansion with improving profitability. Revenue reached 7.5B with 400% growth year-over-year. Profit margins are strong at 496.0%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 400% YoY, reaching 7.5B. This pace significantly outperforms most DRUG MANUFACTURERS - GENERAL peers.
ROE of 589.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can Grifols SA ADR maintain 400%+ revenue growth, or will competition slow it down?
Debt management: total debt of 9.7B is significantly higher than cash (623M). Monitor refinancing risk.
Sector dynamics: monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive moves, and regulatory changes that could impact Grifols SA ADR.
Bottom Line
Grifols SA ADR offers an attractive blend of growth (400% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Grifols SA ADR(GRFS)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
USA
Grifols, SA is dedicated to obtaining, manufacturing, preparing and selling therapeutic products, mainly blood derivatives. The company is headquartered in Barcelona, Spain.